利拉鲁肽对伴或不伴心梗或卒中史的2型糖尿病患者心血管结局的影响
LEADER试验事后分析纳入9340例心血管高危的2型糖尿病患者,按心梗/卒中史、已确诊动脉粥样硬化性心血管病但无心梗/卒中史、仅有心血管危险因素分组。利拉鲁肽较安慰剂降低有心梗/卒中史者(HR 0.85,95%CI 0.73-0.99)及已确诊ASCVD但无心梗/卒中史者(HR 0.76,95%CI 0.62-0.94)的主要不良心血管事件,而仅有危险因素者效果中性(HR 1.08,95%CI 0.84-1.38,Pinteraction=0.11)。
要点
- 利拉鲁肽降低有心梗/卒中史2型糖尿病患者的MACE风险(HR 0.85)。
- 已确诊ASCVD但无心梗/卒中史者同样获益(HR 0.76)。
- 仅有心血管危险因素者利拉鲁肽对MACE效果中性。
核心结论
- 在心血管高危的2型糖尿病患者中,利拉鲁肽降低有心梗/卒中史及已确诊ASCVD但无心梗/卒中史者的心血管结局,对仅有心血管危险因素者效果中性。
研究设计与样本
- LEADER为随机试验,比较利拉鲁肽(1.8 mg或最大耐受剂量)与安慰剂,纳入9340例心血管高危的2型糖尿病患者,中位随访3.8年。
- 本分析为事后分析,按心梗/卒中史、已确诊ASCVD但无心梗/卒中史、仅有心血管危险因素分为三组。
主要发现
- 9340例中,3692例(39.5%)有心梗/卒中史,3083例(33.0%)已确诊ASCVD但无心梗/卒中史,2565例(27.5%)仅有心血管危险因素。
- 主要不良心血管事件发生率:有心梗/卒中史者18.8%(5.0/100患者年),已确诊ASCVD但无心梗/卒中史者11.6%(3.0/100患者年),仅有危险因素者9.8%(2.6/100患者年)。
- 利拉鲁肽组与安慰剂组MACE:有心梗/卒中史者322/1865(17.3%) vs 372/1827(20.4%),HR 0.85(95%CI 0.73-0.99);已确诊ASCVD但无心梗/卒中史者158/1538(10.3%) vs 199/1545(12.9%),HR 0.76(95%CI 0.62-0.94)。
- 仅有危险因素者利拉鲁肽 vs 安慰剂的HR为1.08(95%CI 0.84-1.38,Pinteraction=0.11)。
- 次要结局在各风险组结果相似。
临床怎么用
- 对心血管高危的2型糖尿病患者,若有心梗/卒中史或已确诊ASCVD但无心梗/卒中史,可考虑使用利拉鲁肽以降低MACE风险。
- 仅有心血管危险因素而无明确ASCVD的2型糖尿病患者,利拉鲁肽的心血管获益不明确。
局限性
- 本分析为LEADER试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes). In a post hoc analysis, we evaluated the efficacy of liraglutide in those with and without a history of myocardial infarction (MI) and/or stroke. METHODS: LEADER was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk, with a median follow-up of 3.8 years. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke (major adverse cardiovascular events). Risk groups in this post hoc analysis were defined by history of MI/stroke, established atherosclerotic cardiovascular disease without MI/stroke, or cardiovascular risk factors alone. RESULTS: Of the 9340 patients, 3692 (39.5%) had a history of MI/stroke, 3083 (33.0%) had established atherosclerotic cardiovascular disease without MI/stroke, and 2565 (27.5%) had risk factors alone. Major adverse cardiovascular events occurred in 18.8% of patients with a history of MI/stroke (incidence rate, 5.0 per 100 patient-years), 11.6% of patients with established atherosclerotic cardiovascular disease without MI/stroke (incidence rate, 3.0 per 100 patient-years), and 9.8% of patients with cardiovascular risk factors alone (incidence rate, 2.6 per 100 patient-years). Liraglutide reduced major adverse cardiovascular events in patients with a history of MI/stroke (322 of 1865 [17.3%] versus 372 of 1827 patients [20.4%]; hazard ratio, 0.85; 95% CI, 0.73-0.99) and in those with established atherosclerotic cardiovascular disease without MI/stroke (158 of 1538 [10.3%] versus 199 of 1545 patients [12.9%]; hazard ratio, 0.76; 95% CI, 0.62-0.94) compared with placebo. In patients with risk factors alone, the hazard ratio for liraglutide versus placebo was 1.08 (95% CI, 0.84-1.38, Pinteraction=0.11). Similar results were seen for secondary outcomes across risk groups. CONCLUSIONS: In this post hoc analysis of patients with type 2 diabetes mellitus and high cardiovascular risk, liraglutide reduced cardiovascular outcomes both in patients with a history of MI/stroke and in those with established atherosclerotic cardiovascular disease without MI/stroke. The cardiovascular effect appeared neutral in patients with cardiovascular risk factors alone. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01179048.
引用
- Verma S, Poulter NR, Bhatt DL, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018. PMID: 30566004. doi:10.1161/CIRCULATIONAHA.118.034516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。